Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5877192 | ASTRAZENECA | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
May, 2014
(9 years ago) | |
US6143771 | ASTRAZENECA | Compounds |
May, 2014
(9 years ago) | |
US5877192 (Pediatric) | ASTRAZENECA | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
Nov, 2014
(9 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-138) | Mar 04, 2017 |
New Indication(I-679) | Mar 04, 2017 |
Market Authorisation Date: 31 March, 2005
Treatment: The short term treatment (up to 10 days) in pts having gastroesophageal reflux disease (gerd) as an alternative to oral therapy in pts when therapy with nexium capsules is not possible or appropriate
Dosage: INJECTABLE;INTRAVENOUS